Ranked #2,922 of 8,699 institutional investors
First Turn Management, LLC
Del Mar, CA
$718M
US stock portfolio at live prices · today +$8.2M (+1.15%)
Market closed. Prices as of Nov 20, 6:41 AM ET
- Value at quarter end (Q3 2026)
- $753M
- Change from Q2 2026
- −$181.7M (−19.44%)
- Positions
- 34 · 13 new, 4 sold out
- Filed
- Nov 16, 2026
Not counted in the ranking: none$76.8M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesVRDN 6.68%ELVN 6.19%INSM 4.94%UTHR 4.68%GH 4.45%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| VRDN Viridian Therapeutics, Inc. | 1,525,220 | $48.0M | 6.68% | Reduced −9% |
| ELVN Enliven Therapeutics, Inc. | 958,700 | $44.5M | 6.19% | Added +0% |
| INSM Insmed Incorporated | 245,726 | $35.5M | 4.94% | Reduced −7% |
| UTHR United Therapeutics Corporation | 60,064 | $33.6M | 4.68% | Reduced −29% |
| GH Guardant Health, Inc. | 219,304 | $31.9M | 4.45% | New |
| ABVX ABIVAX Société Anonyme | 384,592 | $31.0M | 4.32% | Reduced −21% |
| CRL Charles River Laboratories International, Inc. | 86,801 | $28.5M | 3.96% | New |
| BBIO BridgeBio Pharma, Inc. | 354,371 | $27.7M | 3.86% | Reduced −44% |
| PRAX Praxis Precision Medicines, Inc. | 78,806 | $24.5M | 3.41% | Reduced −6% |
| AXSM Axsome Therapeutics, Inc. | 162,407 | $22.0M | 3.07% | Reduced −26% |
| CELC Celcuity Inc. | 329,101 | $18.5M | 2.58% | Unchanged |
| RGEN Repligen Corporation | 108,436 | $18.5M | 2.57% | New |
| CYTK Cytokinetics, Incorporated | 357,945 | $18.4M | 2.56% | Reduced −32% |
| RYTM Rhythm Pharmaceuticals, Inc. | 157,603 | $18.4M | 2.56% | Added +2% |
| TNGX Tango Therapeutics, Inc. | 766,860 | $17.4M | 2.42% | New |
| MANE Veradermics Inc | 136,718 | $17.0M | 2.37% | New |
| IRON Disc Medicine, Inc. | 220,666 | $16.8M | 2.34% | New |
| PVLA Palvella Therapeutics, Inc. | 109,871 | $16.0M | 2.23% | Reduced −30% |
| DNTH Dianthus Therapeutics, Inc. | 178,573 | $15.1M | 2.11% | Reduced −38% |
| RVMD Revolution Medicines, Inc. | 92,316 | $14.7M | 2.05% | Reduced −78% |
| COGT Cogent Biosciences, Inc. | 514,976 | $14.3M | 1.99% | Reduced −14% |
| KYMR Kymera Therapeutics, Inc. | 113,299 | $13.5M | 1.88% | Added +11% |
| ERAS Erasca, Inc. | 913,452 | $13.0M | 1.81% | Reduced −25% |
| INBX Inhibrx Biosciences, Inc. | 171,512 | $12.7M | 1.77% | Added +4% |
| ORIC ORIC Pharmaceuticals, Inc. | 1,574,334 | $12.1M | 1.69% | Reduced −22% |
| XENE Xenon Pharmaceuticals Inc. | 297,060 | $11.2M | 1.55% | Reduced −51% |
| SYRE Spyre Therapeutics, Inc. | 102,541 | $10.0M | 1.39% | New |
| GRAL GRAIL, Inc. | 93,727 | $9.8M | 1.37% | New |
| ARWR Arrowhead Pharmaceuticals, Inc. | 222,649 | $9.7M | 1.35% | New |
| RCUS Arcus Biosciences, Inc. | 577,693 | $9.1M | 1.27% | New |
| HNGE Hinge Health, Inc. | 75,448 | $8.2M | 1.14% | New |
| PCVX Vaxcyte, Inc. | 137,534 | $8.0M | 1.12% | Reduced −69% |
| DFTX Definium Therapeutics, Inc. | 216,531 | $6.4M | 0.89% | New |
| SMMT Summit Therapeutics Inc. | 501,724 | $5.3M | 0.74% | New |